Abstract: Effect of Docetaxel Combined with Oxaliplatin and Capecitabine on Advanced Gastric CancerLiying LIU1, Xiaobing CHEN2, Ming GAO3Correspondence to: Ming GAO, E-mail: gaohaoming033@163.com1Department of Oncology, The First People's Hospital of Zhengzhou, Zhengzhou 450004, China2Department of Oncology, The Cancer Hospital of He'nan Province, Zhengzhou 450008, China3Department of Oncology, The First Affliated Hospital of Zhengzhou University, Zhengzhou 450052, ChinaAbstract Objective: To investigate the response rate and adverse reactions in patients with advanced or metastatic gastric can-cer treated with the regimen of Docetaxel in combination with Oxaliplatin and Capecitabine. Methods: Fifty-six patients were treatedwith the regimen as follows: Docetaxel 75mg/m2, intravenous, day 1; Oxaliplatin 85mg/m2, intravenous, day 2; Capecitabine 1000mg/m2, twice a day, PO, for 14 days, 21 days for each cycle. Evaluation was performed at the end of 2 cyeles. Results: All of these 56 pa-tients were evaluable for response. Six ( 10.7% ) patients achieved complete response ( CR ), 30 ( 53.6% ) patients had partial response( PR ), 12 ( 21.4% ) patients had stable disease ( SD ), 8 ( 14.3% ) patients had disease progression ( DP ), with a total response rate (RR ) of 64.3%. The median progression-free survival was 6.2 months ( 3.6-11.8months ) and the median overall survival time was11.6 months ( 5.9-14.6months ). The most common adverse effects were myelosuppression, gastrointestinal toxicities and neurotoxicity.No chemotherapy-related death was observed. Conclusion: Docetaxel combined with Oxaliplatin and Capecitabine is effective for ad-vanced gastric cancer, with tolerable side effects.Keywords Advanced gastric cancer; Docetaxel; Oxaliplatin; Capecitabine